

Special Issue

Antimicrobial Resistance during the COVID-19 Outbreak

Message from the Guest Editors

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the subsequent pandemic has placed an immense strain on healthcare systems worldwide. The challenges posed by the diagnosis and management of coronavirus disease 2019 (COVID-19) together with concerns regarding associated bacterial and fungal infection have promoted the extensive use of antimicrobials in acute care. In contrast, in the community, we have observed a reduction of antimicrobial use. The impact that the COVID-19 pandemic will have on antimicrobial resistance in the long term remains unknown. We are pleased to invite you to contribute to this Special Issue of *Antibiotics*. The aim of this Special Issue is to provide insights into the impact of COVID-19 on antimicrobial use and antimicrobial resistance. We also aim to highlight and discuss specific interventions that have been developed to address inappropriate antimicrobial use and antimicrobial resistance during the pandemic.

Guest Editors

Dr. Mirela Loredana Grigoraş

Prof. Dr. Cristian Oancea

Dr. Cosmin Citu

Deadline for manuscript submissions

closed (31 October 2023)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/77330

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)